Oslo, Norway, 4 February 2019 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, will announce its fourth quarter and full year 2018 results on Thursday, 14 February 2019. A presentation by Targovax’s management to investors, analysts and the press will take place in Oslo at 10:00 CET.
The quarterly report and the presentation will be available at www.targovax.com in the Investors section from 07:30 CET.
The presentation will take place at 10:00 CET at:
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Simon Conway/Stephanie Cuthbert – FTI Consulting (International)
Phone: +44 20 3727 1000